Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ZGEN, Serono biologics R&D deal

Under a five-year deal, ZymoGenetics (ZGEN) granted Serono (SWX:SEO; SRA) access to a portfolio of genes and proteins for evaluation, screening and licensing for a total of

Read the full 279 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE